Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Publication|Articles|June 18, 2026
Pharmacy Practice in Focus: Oncology
- June 2026
- Volume 8
- Issue 4
Administration of Tivozanib via Gastrostomy Tube: A Pharmacokinetic Analysis
Fact checked by: Kirsty Mackay
This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.
Advertisement
Advertisement
Tivozanib is an oral multikinase inhibitor targeting VEGFR-1,-2, and 3; c-KIT; and PDGFR-b. In the phase 3 TIVO-3 trial, tivozanib improved median progression-free survival (5.6 vs 3.9 months) over sorafenib, leading to FDA approval for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). To our knowledge, there are no published data on the administration of tivozanib via enteral tubes.
Related to this article
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
An investigational glypican-3–directed CAR T-cell therapy engineered to express IL-15 and IL-21 produced a complete response lasting at least 1 year in a child with chemotherapy-resistant metastatic hepatoblastoma.
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Advertisement
Advertisement